Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\21062906
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Clin+Chem
2011 ; 57
(2
): 215-20
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Prediabetes as a therapeutic target
#MMPMID21062906
Pour OR
; Dagogo-Jack S
Clin Chem
2011[Feb]; 57
(2
): 215-20
PMID21062906
show ga
BACKGROUND: The term "prediabetes" is used to describe a condition that involves
impaired glucose tolerance (IGT) or impaired fasting glucose (IFG). IGT is
defined by a 2-h oral glucose tolerance test plasma glucose concentration >140
mg/dL (7.8 mmol/L) but <200 mg/dL (11.1 mmol/L), and IFG is defined by a fasting
plasma glucose concentration ?100 mg/dL (5.6 mmol/L), but <126 mg/dL (7.0
mmol/L). Studies have shown that people with prediabetes tend to develop type 2
diabetes within 10 years and are at increased risk for cardiovascular disease and
death even before the development of diabetes. CONTENT: In this minireview we
discusses the epidemiology, pathophysiology, and clinical implications of
prediabetes. The rationale for therapeutic intervention in people with
prediabetes, the goals of intervention, and the specific tools for intervention
are presented. Emphasis is placed on data from randomized controlled clinical
trials, whenever such data are available. SUMMARY: Approximately 57 million
Americans have prediabetes and are consequently at risk for cardiometabolic
complications. Lifestyle modifications (dietary restriction and exercise) and
certain medications can prevent the development of diabetes in persons with
prediabetes. Lifestyle intervention also has been demonstrated to decrease
cardiovascular disease risk markers, although data on clinical events are
lacking.
|Cardiovascular Diseases/prevention & control
[MESH]
free
free
free
